Shares of AIM ImmunoTech jumped 10.8% to $0.26 after the micro-cap biotech announced it secured patent protection across Europe and the United Kingdom for its immune-modulating drug's use in treating Long COVID, with coverage running through June 2041. The protection became final after a nine-month opposition period under the European Patent Convention closed on August 25, 2026, with no opposition filed. For a company valued at roughly $8 million, the question is whether intellectual property alone can bridge a cavernous gap between promise and commercialization.

  • The Patent Covers a Wide Swath of Europe — But No Drug Is Approved Yet

The granted claims cover 18 countries including Germany, France, Italy, and the UK, protecting specific dosing regimens and delivery methods such as intranasal, intravenous, and inhalation administration. That sounds impressive, but context matters: there are no FDA-approved Long COVID treatments in 2026 , and AIM's drug remains in early-to-mid-stage trials. A Phase 2 trial yielded positive topline results on fatigue reduction , yet a Phase 3 readout — the gold standard for regulatory approval — is still ahead. A patent protects the right to sell, not the ability.

  • The Cash Situation Raises Hard Questions About Runway

During the first half of 2026 alone, AIM raised approximately $10.4 million through multiple equity transactions , yet trailing revenue was just $88,000 against net losses of $14 million.

As of June 30, roughly 48.5 million warrants were outstanding; if exercised, existing shareholders would face significant dilution. The company even removed the cap on its at-the-market stock-sale program in April, allowing unlimited share issuance — a lifeline, but one that steadily erodes ownership for current holders.

  • The IP Strategy Is Getting Broader, But Revenue Remains Theoretical

This European patent follows a newly issued U.S. patent covering the drug in combination with a leading cancer immunotherapy, broadening the global IP estate across multiple therapeutic areas. CEO Thomas Equels called the portfolio "increasingly valuable." Yet an estimated 7–23 million Americans still live with Long COVID and the market lacks any approved treatment — meaning the commercial opportunity is real but entirely unproven for any company, let alone one burning cash at this rate.

  • A 10.8% Pop on Patent News Tells You What Kind of Stock This Is The stock bounced from $0.23 to $0.26 on headlines — the same price it traded at just days earlier. Over the past 12 months, shares have lost 95.4%. For investors, this is a speculative bet that AIM can survive long enough to convert patents into an approved product. The 2041 expiration date sounds durable; the balance sheet does not.